Role of Faascin protein in proliferation and invasion of hepatocellular carcinoma.

Faascin 蛋白在肝细胞癌增殖和侵袭中的作用。

基本信息

  • 批准号:
    20591614
  • 负责人:
  • 金额:
    $ 2.91万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2008
  • 资助国家:
    日本
  • 起止时间:
    2008 至 2010
  • 项目状态:
    已结题

项目摘要

BACKGROUND : Fascin is an actin-bundling protein and induces membrane protrusions and cell motility after the formation of lamellipodia or filopodia. Fascin expression has been reported to be associated with progression or prognosis in various neoplasms, but the role of fascin in hepatocellular carcinoma (HCC) remains unknown. The aim of this study was to investigate the clinicopathological and prognostic relevance of fascin by immunohistochemistry. METHODS : A total of 137 patients with HCC were stained with anti-fascin antibody. The tumor cells having unequivocal cytoplasmic and/or membranous fascin immunoreactivity were defined as fascin-positive. RESULTS : Immunohistochemically, 23 (16.8%) HCCs having unequivocal fascin immunoreactivity were found. Tumors showing fascin expression were larger and less differentiated than those showing no fascin expression (P=0.0239 and 0.0018, respectively). Portal venous invasion, bile duct invasion, and intrahepatic metastasis were detected significantly more frequently in fascin-positive group (P=0.0029, 0.0333, and 0.0403, respectively). In addition, high alpha-fetoprotein (AFP) levels were significantly associated with the fascin expression in HCC (P=0.0116). Fascin-positive group had significantly poorer outcomes than fascin-negative group and was an independent prognostic factor for disease-free survival. CONCLUSIONS : Fascin might become a novel marker of progression in HCC and a significant indicator of a poor prognosis for patients with HCC.
背景:肌成束蛋白是一种肌动蛋白束蛋白,在片状伪足或丝状伪足形成后可诱导细胞膜突起和细胞运动。Fascin表达与多种肿瘤的进展或预后相关,但Fascin在肝细胞癌(HCC)中的作用仍不清楚。本研究的目的是通过免疫组化研究肌成束蛋白的临床病理学和预后相关性。方法:用抗fascin抗体对137例HCC患者进行染色。具有明确的细胞质和/或膜成束蛋白免疫反应性的肿瘤细胞被定义为成束蛋白阳性。研究结果:免疫组化结果显示,23例(16.8%)肝细胞癌呈明确的fascin免疫反应阳性,fascin阳性表达的肝细胞癌比无fascin表达的肝细胞癌更大,分化程度更低(P分别为0.0239和0.0018)。Fascin阳性组门静脉侵犯、胆管侵犯和肝内转移的发生率明显高于阴性组(P分别为0.0029、0.0333和0.0403)。此外,高甲胎蛋白(AFP)水平与HCC中Fascin的表达显著相关(P=0.0116)。Fascin阳性组的预后显著差于Fascin阴性组,是无病生存的独立预后因素。结论:Fascin可能成为HCC进展的新标志物和HCC患者预后不良的重要指标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CX3CL1 (Fractalkine): A Signpost for Biliary Inflammation in Primary Biliary Cirrhosis
  • DOI:
    10.1002/hep.23318
  • 发表时间:
    2010-02-01
  • 期刊:
  • 影响因子:
    13.5
  • 作者:
    Shimoda, Shinji;Harada, Kenichi;Akashi, Koichi
  • 通讯作者:
    Akashi, Koichi
Donor Risk in Adult-to-Adult Living Donor Liver Transplantation: Impact of Left Lobe Graft
  • DOI:
    10.1097/tp.0b013e3181943d46
  • 发表时间:
    2009-02-15
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Taketomi, Akinobu;Kayashima, Hiroto;Maehara, Yoshihiko
  • 通讯作者:
    Maehara, Yoshihiko
Stage IV肝細胞癌に対する治療戦略決定のための予後予測システムの構築
IV期肝细胞癌治疗策略的预后预测系统的构建
  • DOI:
  • 发表时间:
    2009
  • 期刊:
  • 影响因子:
    0
  • 作者:
    武冨紹信;森田和豊;梅田健二;永田茂行;杉町圭史;池上徹;祇園智信;副島雄二;調憲;前原喜彦
  • 通讯作者:
    前原喜彦
Improved Results of a Surgical Resection for the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation
  • DOI:
    10.1245/s10434-010-0999-y
  • 发表时间:
    2010-09-01
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Taketomi, Akinobu;Fukuhara, Takasuke;Maehara, Yoshihko
  • 通讯作者:
    Maehara, Yoshihko
胆道合併症ゼロを目指した生体肝移植ドナー肝切除の工夫
活体肝移植供体肝切除术的改进旨在实现零胆道并发症
  • DOI:
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    0
  • 作者:
    武冨紹信;他
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAKETOMI Akinobu其他文献

TAKETOMI Akinobu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAKETOMI Akinobu', 18)}}的其他基金

Development of extracorporeal therapeutic method of liver grafts using siRNA during machine perfusion preservation
机器灌注保存期间使用siRNA的肝移植体外治疗方法的发展
  • 批准号:
    25670547
  • 财政年份:
    2013
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Treatment strategies of recurrent hepatitis C after liver transplantation based on IL28B singlencleotide polymorphism.
基于IL28B单核苷酸多态性的肝移植术后复发丙型肝炎治疗策略
  • 批准号:
    23390328
  • 财政年份:
    2011
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Role of diacylglycerol kinase delta in hepatocarcinogenesis
二酰甘油激酶δ在肝癌发生中的作用
  • 批准号:
    16591327
  • 财政年份:
    2004
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Preoperative immunotherapy in Hepatocellular Carcinoma
肝细胞癌的术前免疫治疗
  • 批准号:
    10578074
  • 财政年份:
    2023
  • 资助金额:
    $ 2.91万
  • 项目类别:
Development of new biomarkers to predict the therapeutic efficacy and prognosis of systemic chemotherapy for hepatocellular carcinoma
开发新的生物标志物来预测肝细胞癌全身化疗的疗效和预后
  • 批准号:
    23K15068
  • 财政年份:
    2023
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Defining pro-metastatic and endothelial-regulatory roles for LIN28B in hepatocellular carcinoma
定义 LIN28B 在肝细胞癌中的促转移和内皮调节作用
  • 批准号:
    10865508
  • 财政年份:
    2023
  • 资助金额:
    $ 2.91万
  • 项目类别:
Mechanisms that promote hepatocellular carcinoma due to chronic ethanol exposure
长期接触乙醇促进肝细胞癌的机制
  • 批准号:
    10666121
  • 财政年份:
    2023
  • 资助金额:
    $ 2.91万
  • 项目类别:
Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma
开发和自动化基于细胞外囊泡的测试以早期检测肝细胞癌
  • 批准号:
    10823687
  • 财政年份:
    2023
  • 资助金额:
    $ 2.91万
  • 项目类别:
Click Chemistry-Mediated Surface Protein Assay for Quantifying Subpopulations of Hepatocellular Carcinoma-associated Extracellular Vesicles
点击化学介导的表面蛋白测定法定量肝细胞癌相关细胞外囊泡亚群
  • 批准号:
    10737497
  • 财政年份:
    2023
  • 资助金额:
    $ 2.91万
  • 项目类别:
Bacterial DNA as a Diagnostic Biomarker of Hepatocellular Carcinoma
细菌 DNA 作为肝细胞癌的诊断生物标志物
  • 批准号:
    10557105
  • 财政年份:
    2022
  • 资助金额:
    $ 2.91万
  • 项目类别:
Sphingosine kinase 2 in sexual dimorphism of hepatocellular carcinoma
鞘氨醇激酶2在肝细胞癌性别二态性中的作用
  • 批准号:
    10521724
  • 财政年份:
    2022
  • 资助金额:
    $ 2.91万
  • 项目类别:
Determining the influence of sex and gender in hepatocellular carcinoma risk and survival
确定性别和性别对肝细胞癌风险和生存的影响
  • 批准号:
    10652647
  • 财政年份:
    2022
  • 资助金额:
    $ 2.91万
  • 项目类别:
Preclinical development of CXCR6 antagonists to target sorafenib resistance in Hepatocellular Carcinoma
针对肝细胞癌索拉非尼耐药性的 CXCR6 拮抗剂的临床前开发
  • 批准号:
    10435160
  • 财政年份:
    2022
  • 资助金额:
    $ 2.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了